Amarin Corporation plc – Trademark Portfolio
Entity Type: 03
Amarin Corporation plc holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 11 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include AMARIN. The owner is based in London.
7 Curzon Street
London W1J 5HG , GB
Showing of trademarks Trademarks
Trademark Classifications
Amarin Corporation plc's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Amarin Corporation plc have?
Amarin Corporation plc has 17 U.S. trademarks filed with the USPTO. Of these, 2 registered, 13 abandoned, 2 cancelled.
What trademark classes does Amarin Corporation plc file in?
Amarin Corporation plc files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 40 (Treatment & Processing). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Amarin Corporation plc's most well-known trademarks?
Amarin Corporation plc's registered trademark portfolio includes well-known marks such as AMARIN. These are among 2 currently registered trademarks in the portfolio.
What is Amarin Corporation plc's trademark registration success rate?
Amarin Corporation plc has a 12% trademark registration rate, with 2 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.